1.Cutaneous Squamous Cell Carcinoma (CSCC): For metastatic or locally advanced disease not amenable to curative surgery or radiation.

2.Basal Cell Carcinoma (BCC): For locally advanced or metastatic disease after hedgehog pathway inhibitor therapy or when such therapy is not appropriate.

3.Non-Small Cell Lung Cancer (NSCLC):

In combination with platinum-based chemotherapy for first-line treatment in patients without EGFR, ALK, or ROS1 aberrations.

As monotherapy for first-line treatment in patients with high PD-L1 expression (TPS ≥50%) without EGFR, ALK, or ROS1 aberrations.

Administer as an intravenous infusion over 30 minutes.

CSCC and BCC: 350 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.

NSCLC: 350 mg every 3 weeks until disease progression or unacceptable toxicity.

Dose modifications or discontinuation may be required based on severity of immune-mediated adverse reactions.